Live news related to AB SCIENCE stock (FR0010557264): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The latest financial news on AB SCIENCE mainly cover M&A activity et analyst notes. The stock trades at €0,51 on Euronext Paris, down 2,48% at the last update. This page lists the articles published on AB SCIENCE stock to track the share price, company announcements and any item likely to influence market perception.
AB Science has announced the discontinuation of three non-priority clinical studies of masitinib, in order to focus its resources on two programs: AB8…
AB Science restructured its governance on July 7, 2026, by appointing Stéphane Ledermann as the CEO and Chairman, a shareholder for over fourteen year…
AB Science announced on Wednesday the successful completion of a private placement of €2.3 million with institutional investors. This capital increase…
AB Science announced on Monday the completion of stage 3 of its phase 1 clinical trial evaluating the combination of AB8939 and venetoclax in the trea…
AB Science announced on Wednesday that it has been granted a U.S. patent protecting masitinib until May 2042 for the treatment of hormone-resistant me…
AB Science announced on Tuesday that new analyses of its phase 3 trial on masitinib in amyotrophic lateral sclerosis will be presented at the 2026 ann…
Stonegate Capital Partners, an independent US-based research firm, updated its coverage of AB Science's stock on Tuesday following the release of the …
Maxim Group reaffirmed its buy recommendation for AB Science on Monday, with a target price of €4.00 per share. The analysis report, published on May …
AB Science announced its annual results for 2025, showing a non-recurring operating deficit reduced to €3.8 million, a 38% decrease from 2024. Includi…
AB Science announces the successful completion of a capital increase of 3.2 million euros with a select group of investors. The funds raised will prim…
